Home
Search:
1146 feeds
357 categories
0 articles (<24 hours)
33 registered users

Use the Mobile version
Mobile

Follow our Twitter feed

View our Linkpartners
Links

Username:
Password:

Register | Retrieve

General


RSS FeedsFDA approves Rituxan Hycela (rituximab and hyaluronidase human) for subcutaneous injection in certain blood cancers
(WorldNews Switzerland)

 
 

23 june 2017 08:11:31

 
FDA approves Rituxan Hycela (rituximab and hyaluronidase human) for subcutaneous injection in certain blood cancers
(WorldNews Switzerland)
 


Basel, 23 June 2017 FDA approves Rituxan Hycela (rituximab and hyaluronidase human) for subcutaneous injection in certain blood cancers Treatment can be administered in five to seven minutes, compared to 1.5 hours or more for intravenous Rituxan Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) approved Rituxan HycelaTM (rituximab and hyaluronidase human) for subcutaneous (under the skin) injection, for the treatment of adults with the following blood cancers: previously untreated and relapsed or refractory follicular lymphoma, previously untreated diffuse large B-cell lymphoma (DLBCL), and previously untreated and previously treated chronic...


 
19 viewsCategory: General > Europe > Switzerland
 
New data at EAN show Roche´s OCREVUSTM (ocrelizumab) significantly reduced multiple measures of disease progression in relapsing and primary progressive multiple sclerosis
(WorldNews Switzerland)
Julius Baer integrates WMPartners and broadens its multi-custody wealth management capabilities
(WorldNews Switzerland)
 
 
blog comments powered by Disqus


Copyright © 2008 - 2024 Indigonet Services B.V.. Contact: Tim Hulsen. Read here our privacy notice.
Other websites of Indigonet Services B.V.: Nieuws Vacatures Science Tweets Nachrichten